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LONG-TERM FOLLOW UP OF T CELL DEPLETED TRANSPLANTS FROM
UNRELATED DONORS IN PEDIATRIC PATIENTS
Hale, G.A.1, Krance, R.A.2,3,4, Khan, S.P.2,3, Rochester, R.1,
Horwitz, E.M.1, Turner, V.1, Gee, A.P.2,3,4, Brenner, M.K.2,3,4,
Heslop, H.E.2,3,4 1St Jude Children’s Research Hospital, Memphis, TN;
2Baylor College of Medicine, Houston, TX; 3Texas Children’s Hospital,
Houston, TX; 4The Methodist Hospital, Houston, TX.
Graft-versus-host disease (GVHD) remains a major cause of
mortality and long term morbidity in recipients of hematopoietic
stem cell transplant from unrelated donors. From 1993-2000 we
used partial T cell depletion to reduce this risk and transplanted
116 patients with T cell depleted unrelated donor stem cells on two
successive IRB-approved protocols at St Jude Children’s Research
Hospital (1993-1997 n  75) and Baylor College of Medicine
(1998-2000 n 41). All patients were transplanted for hematologic
malignancy and were stratiﬁed into standard risk (Acute leukemia
or lymphoma in 1st or 2nd remission or CML in 1st chronic phase)
or high risk (Acute leukemia or lymphoma in relapse or  CR3,
CML beyond 1st chronic phase, myelodysplasia or secondary
AML). Patients received marrow from 5/6 or 6/6 matched unre-
lated donors depleted of T cells by incubation with CD6 and CD8
antibodies and baby rabbit complement, which produced a median
T cell depletion of 96%. Conditioning was with Cyclophospha-
mide 45mg/kg x 2, Ara-C 3g/m2 x 6, ATG 30mg/kg x 3 and TBI
1200-1400cGy. In 1997 we reported initial outcome data in the
ﬁrst 51 patients (Hongeng et al Lancet 1997, 350: 767-71 ) with a
2-year disease-free survival estimate for standard-risk recipients of
73	12.1% and for high risk recipients of 32 	 15.1%. We now
report long term follow up on all 116 patients with follow up
ranging between 6.7 and 13.5 years. The 5 and 10 year Kaplan
Meier survival estimate is 60% for 49 standard risk patients and
37% for 67 high risk patients. 4 of the 49 standard risk patients and
26 of the 67 high risk patients relapsed. Three of the patients who
relapsed are long term survivors after relapse ( 10 years) after
donor lymphocyte infusion. All but one relapse occurred within 2
years of transplant. The incidence of grade 3-4 GVHD was 5%
and only 4% of recipients developed extensive chronic GVHD.
The 100 day mortality was 21% in high risk recipients and 19% in
standard risk recipients but the incidence of late non-relapse mor-
tality was low with only two deaths from causes other than relapse
after one year - one death from pulmonary failure at 4.5 years and
one at 10 years in a motor vehicle accident. All long term survivors
have a good performance status. Partial T cell depletion can there-
fore reduce the risk of graft versus host disease and long term
sequelae from this complication without an increased risk of re-
lapse.
IMMUNE RECONSTITUTION
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INSULIN-LIKE GROWTH FACTOR I POSITIVELY REGULATES THYMIC
FUNCTION BY EXPANSION OF THYMOCYTE PRECURSORS AND THYMIC
EPITHELIAL CELLS
Chu, Y.-W.1, Schmitz, S.1, Choudhury, B.1, Gress, R.E.1 1Experimen-
tal Transplantation and Immunology Branch, National Cancer Institute,
Bethesda, MD.
Neuroendocrine growth factors help regulate thymic function
and serve as potential agents to accelerate thymic T-cell produc-
tion following hematopoietic stem cell transplantation (HSCT).
We present evidence supporting insulin-like growth factor I
(IGF-1) as a thymic regulator. Continuous infusion of IGF-1 (100
ug/day) into normal mice resulted in signiﬁcant increases in all
thymocyte populations, including earliest thymocyte precursors
(ETP), with subsequent increases in recent thymic emigrants
(RTE). Time-sequential enumeration of thymic epithelial cell
(TEC) and thymocyte subpopulations and bone marrow and pe-
ripheral LSK (Lineage-, Sca-1, c-kit) precursor populations
showed that expansion of peripheral LSK, occurring on day 4 of
IGF-1 administration, preceded quantitative increases in thymo-
cyte and TEC subpopulations by three days. Concomitant with the
increase in peripheral LSK numbers, cell cycle entry was increased
in bone marrow and peripheral LSK and lineage-CD44 CD25
(DN2) thymocytes. IGF-1 administration also affected TEC turn-
over during this early time period (day 2-7) preceding numeric
increases in TEC. The relative proportions of cortical and med-
ullary TEC were not altered throughout the course of IGF-1
administration. Finally, mice lacking IGF-1 receptor (IGF-1R)
signaling on T-cells were generated through cre-mediated deletion
of the IGF-1R high-afﬁnity binding site (pLCK-cre/loxIGF1R).
Compared to wild-type littermates, pLCK-cre-loxIGF1R mice ex-
hibited a decrease in the number of CD4CD8 thymocytes,
thymic TREC, and splenic naı¨ve T-cells and RTE. IGF-1 treat-
ment, however, restored thymocyte and peripheral subset numbers
in these mice. These results demonstrate: 1) IGF-1 expands thy-
mocyte subpopulations and increases thymic output; 2) IGF-1
expands peripheral thymocyte precursor populations leading to
their increased availability for entry into the thymus; and 3)
IGF-1R signaling is required for the maintenance of normal thy-
mocyte and peripheral T-cell populations, and that presumptive
IGF-1 effects on TEC can overcome the absence of IGF-1R
signaling in thymocytes. Together, the results support the concept
of neuroendocrine growth factors such as IGF-1 in preserving
and/or enhancing thymic function recovery following HSCT, and
suggest that points of regulation in thymic function by IGF-1
include entry of thymocyte precursors into the thymus and the
proportionate expansion of TEC populations that facilitate thymo-
cyte development.
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A SUBPOPULATION OF HUMAN NK CELLS LACKING INHIBITORY RE-
CEPTORS FOR SELF MHC IS DEVELOPMENTALLY IMMATURE RATHER
THAN AUTOREACTIVE
Cooley, S.A.1, Xiao, F.1, Bergemann, T.L.3, Pitt, M.1, Gleason, M.1,
McCullar, V.1, McQueen, K.2, Guethlein, L.2, Parham, P.2,
Miller, J.S.1 1Division of Hematology, Oncology and Transplantation,
University of Minnesota Cancer Center, Minneapolis, MN; 2Stanford
University, Palo Alto, CA; 3Division of Biostatistics, School of Public
Health, University of Minnesota, Minneapolis, MN.
The effector function of human natural killer (NK) cells is
down-regulated via ligation of inhibitory receptors (killer immu-
noglobulin-like receptors [KIR] and NKG2A) that recognize self
MHC. In order to study the mechanism producing self-tolerance,
which is not yet understood., we developed and validated a quan-
titative, real-time RT-PCR (Q-RT-PCR) assay to measure mRNA
levels from individual NKG2 and KIR genes. Our expression typing
assay accurately predicts genotyping by SSOP (sensitivity 0.94.
speciﬁcity 0.96, PPV 0.97) and gives expression data with a single
quantitative readout. We used this assay to investigate NK cells
circulating in normal blood. We sorted CD56dim NK cells into
KIR and KIR- subsets by ﬂow cytometry using an antibody
cocktail recognizing 6 KIR. Measurements of individual KIR gene
expression showed that not all CD56dim cells express KIR. The
KIR- populations were further divided into NKG2A positive and
negative cells, deﬁning a novel subpopulation of cells committed to
the NK lineage. This KIR- NKG2A- subset comprises 19.4	 2.8%
of CD56dim NK cells in healthy donors, and expresses the acti-
vating NKG2D and NKG2E receptors. Consequently these
CD56
dim
NKG2A-KIR- NK cells do not have ‘at least one’ inhib-
itory receptor for engaging autologous MHC class I. However,
they are not intolerant, autoreactive cells, but instead are imma-
ture, already committed NK cells (based on CD56 expression),
coexpressing CD7, CD16, and CD18. Functional assays showed
this population to be hyporesponsive. Compared to KIR or
NKG2A-expressing subsets, they exhibited impaired degranulation
(measured by CD107a) and poor cytotoxicity against K562 targets.
Furthermore, they produced little IFN- after stimulation with
IL-12 and IL-18, and compared to that of CD56dim NK cells that
express NKG2A, they showed a diminished capacity to proliferate
in response to IL-15. Upon culture on a murine embryonic stromal
cell line with IL-15, these CD56dim NKG2A-KIR- NK cells
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